Pharmaceuticals News and Research

RSS

Kentucky researcher uses advanced biomedical technology to study HMPV

You may not know the human metapneumovirus by name, but chances are that you have met somewhere before.

22 Aug 2013

New antibody drug shows positive results for treating Crohn's disease, ulcerative colitis

Vedolizumab, a new intravenous antibody medication, has shown positive results for treating both Crohn's disease and ulcerative colitis, according to researchers at the University of California San Diego, School of Medicine. The findings, published in two papers, will appear in the August 22 issue of the New England Journal of Medicine (NEJM).

22 Aug 2013

Oramed starts patient recruitment in Israel for ORMD-0801 clinical trial for patients with T1DM

Oramed Pharmaceuticals Inc., a developer of oral drug delivery systems, announced today that it has initiated patient recruitment for a new clinical trial of its orally ingestible insulin capsule, ORMD-0801 for patients with type 1 diabetes mellitus in Israel.

22 Aug 2013

Three University of Sydney research teams win NHMRC Centres of Research Excellence

World-changing collaborative research in the areas of youth mental health, metabolic health and sleep medicine have seen three research teams at the University of Sydney funded for five years as NHMRC Centres of Research Excellence.

21 Aug 2013

RTI International takes initiatives to understand long-term effects of TBI in military members, veterans

As part of a federal initiative to better understand traumatic brain injuries suffered by the nation's military service members and veterans, researchers at RTI International will join a consortium led by Virginia Commonwealth University to better understand the long-term effects of chronic mild brain injuries, or concussions.

21 Aug 2013

Oncopeptides launches phase II study to determine efficacy of melflufen in treatement of multiple myeloma

Oncopeptides AB, a company working to enhance oncology therapies, today announced that the first patient has been dosed as part of a Phase II study in multiple myeloma patients with its drug candidate melflufen (previously called J1).

21 Aug 2013

Montana researcher receives $1M army grant to develop drug that limits damage caused by TBI

The U.S. Army has awarded University of Montana researcher Dave Poulsen a $1 million grant to further develop a drug that limits damage caused by traumatic brain injuries.

21 Aug 2013

UCLA study suggests third possible cause for AD: Iron accumulation

Alzheimer's disease has proven to be a difficult enemy to defeat. After all, aging is the No. 1 risk factor for the disorder, and there's no stopping that.

21 Aug 2013

Twice-daily KALYDECO improves lung function in people with cystic fibrosis

Vertex Pharmaceuticals (Australia) Pty Ltd., announces the presentation of data from KALYDECO (ivacaftor) studies at the 10th Australasian Cystic Fibrosis Conference in Auckland, New Zealand, August 17 – 20, 2013, which further demonstrate the benefits of the medicine in people with cystic fibrosis ages 6 and older who have at least one copy of the G551D mutation in the cystic fibrosis transmembrane conductance regulator gene.

21 Aug 2013

UC Davis graduate discovers how eIF4E protein acts upon cancer-promoting mRNA molecules

Researchers have long known that high levels of a specific protein in human cells are linked to tumor growth - but no one has fully understood how.

21 Aug 2013

Tel-Aviv Stock Exchange approves new listing of OPKO's common stock

OPKO Health, Inc. (NYSE: OPK), a multi-national biopharmaceutical and diagnostics company, today announced that the Tel-Aviv Stock Exchange ("TASE") has approved the new listing of OPKO's common stock on the TASE beginning on August 21, 2013, under the ticker symbol OPK. OPKO's common stock will thereafter be listed on both the NYSE in the United States and the TASE in Israel.

19 Aug 2013

Tigercat and Velocity Pharmaceutical announce submission of IND application to FDA for VPD-737

Velocity Pharmaceutical Development, LLC ("VPD") and Tigercat Pharma, Inc., ("Tigercat") announced today the submission of an Investigational New Drug (IND) application to the US Food and Drug Administration (FDA) for VPD-737 for the treatment of chronic pruritus.

19 Aug 2013

VPD and Remeditex Ventures sign collaboration agreement

Velocity Pharmaceutical Development, LLC ("VPD") and Remeditex Ventures, LLC ("Remeditex") announced today the signing of a collaboration agreement. Under this agreement, VPD and Remeditex will jointly evaluate pharmaceutical development opportunities for management by the VPD development team and potential funding from Velocity Pharmaceutical Holdings, LLC and Remeditex.

19 Aug 2013

Over 1,700 new chiral HPLC/SFC applications added to Phenomenex’s online resource

Phenomenex Inc., a global leader in the research and manufacture of advanced technologies for the separation sciences, announces the addition of over 1,700 new chiral HPLC/SFC applications to its online resource, including more than 400 new SFC (supercritical fluid chromatography) methods. Phenomenex’s extensive chiral application database is unique in the industry, particularly with the addition of the SFC methods, which were developed in collaboration with the Department of Analytical Chemistry and Pharmaceutical Technology, Vrije Universiteit Brussel, Brussels, Belgium.

19 Aug 2013

Second GSK intramuscular quadrivalent influenza vaccine approved by the FDA

GlaxoSmithKline plc [LSE/NYSE: GSK] announced that the U.S. Food and Drug Administration (FDA) has approved FLULAVAL® QUADRIVALENT (Influenza Virus Vaccine) for the active immunization of persons three years of age and older to help prevent disease caused by seasonal influenza (flu) virus subtypes A and B contained in the vaccine.

19 Aug 2013

New type of cancer immunotherapy harnesses body's immune system to attack tumors

By carefully adjusting the function of crucial immune cells, scientists may have developed a completely new type of cancer immunotherapy—harnessing the body's immune system to attack tumors. To accomplish this, they had to thread a needle in immune function, shrinking tumors without triggering unwanted autoimmune responses.

19 Aug 2013

Boehringer signs agreement with Brigham to conduct long-term study program on oral anticoagulants

Boehringer Ingelheim, a research-based, global pharmaceutical company, today announced a multi-year agreement with Brigham and Women's Hospital, an internationally recognized teaching affiliate of Harvard Medical School known for its excellence in patient care, medical research and training of outstanding young health professionals.

17 Aug 2013

Pharmaceuticals News and Research

Kentucky researcher uses advanced biomedical technology to study HMPV

New antibody drug shows positive results for treating Crohn's disease, ulcerative colitis

Oramed starts patient recruitment in Israel for ORMD-0801 clinical trial for patients with T1DM

Three University of Sydney research teams win NHMRC Centres of Research Excellence

RTI International takes initiatives to understand long-term effects of TBI in military members, veterans

Oncopeptides launches phase II study to determine efficacy of melflufen in treatement of multiple myeloma

Montana researcher receives $1M army grant to develop drug that limits damage caused by TBI

UCLA study suggests third possible cause for AD: Iron accumulation

Twice-daily KALYDECO improves lung function in people with cystic fibrosis

UC Davis graduate discovers how eIF4E protein acts upon cancer-promoting mRNA molecules

Tel-Aviv Stock Exchange approves new listing of OPKO's common stock

Tigercat and Velocity Pharmaceutical announce submission of IND application to FDA for VPD-737

VPD and Remeditex Ventures sign collaboration agreement

Over 1,700 new chiral HPLC/SFC applications added to Phenomenex’s online resource

Second GSK intramuscular quadrivalent influenza vaccine approved by the FDA

New type of cancer immunotherapy harnesses body's immune system to attack tumors

Boehringer signs agreement with Brigham to conduct long-term study program on oral anticoagulants

FDA grants Orphan Drug Designation to Alnylam ALN-AT3 for treatment of hemophilia B

Arrays of nanoscale sensors detect flaws in drugs and help improve production

UCSF study shows potential for new treatment strategy for Parkinson’s disease

Event guide: World ADC Asia eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence